A PHASE 1B STUDY OF THE 4-1BB AGONIST PF-05082566 IN COMBINATION WITH THE PD-1 INHIBITOR MK-3475 IN PATIENTS WITH ADVANCED SOLID TUMORS
Phase of Trial: Phase I
Latest Information Update: 15 Feb 2019
Price : $35 *
At a glance
- Drugs Pembrolizumab (Primary) ; Utomilumab (Primary)
- Indications Colon cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Pancreatic cancer; Renal cell carcinoma; Sarcoma; Small cell lung cancer; Solid tumours; Thymoma; Thyroid cancer
- Focus Adverse reactions
- Acronyms KEYNOTE-0036
- Sponsors Pfizer
- 14 Mar 2017 Status changed from active, no longer recruiting to completed.
- 23 Feb 2017 Planned number of patients changed from 23 to 45.
- 23 Feb 2017 Planned End Date changed from 1 Mar 2017 to 1 Feb 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History